Effective Management of Chronic Low Back Pain in the Elderly: A One-Year Cohort Study of Oxygen-Ozone Therapy Under CT Guidance Combined with Alpha Lipoic Acid, Palmitoylethanolamide, and Myrrh
Observational studyHumansWith alpha-lipoic acid and myrrh, alongside CT-guided oxygen-ozone paravertebral injections
This study tested palmitoylethanolamide together with alpha-lipoic acid and myrrh, alongside CT-guided oxygen-ozone paravertebral injections. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Observational study
- Subjects
- 276 patients aged 65 to 92 years with chronic unilateral or bilateral low back pain
- Dose used in the study
- Oral alpha-lipoic acid 800 mg/day, PEA 600 mg/day, myrrh 200 mg/day, alongside CT-guided oxygen-ozone paravertebral injections
- Duration
- 30-day oral regimen; outcomes followed at one month and one year
- What was measured
- Pain (Visual Analog Scale) and functional outcome (modified McNab method) at one month and one year after treatment. 276 patients aged 65 to 92 with chronic low back pain received CT-guided oxygen-ozone paravertebral injections plus a 30-day oral regimen of alpha-lipoic acid (800 mg/day), PEA (600 mg/day) and myrrh (200 mg/day).
What the authors reported
At one month, 32.94% of patients reported excellent improvement, with mean VAS falling from 8.17 to 2.81. At one year, 68.15% had a cumulative positive outcome, 17.78% had complete pain resolution, and mean VAS was 3.57.
Limits of this study
An observational cohort study with no control group, combining PEA with ozone injections, alpha-lipoic acid and myrrh, so PEA's individual contribution cannot be separated. The authors declare no conflicts of interest.
Source
PubMed 40427076 · doi:10.3390/biomedicines13051250
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.